Better Method Found to Determine Bone Marrow Involvement in DLBCL

Researchers have discovered a better way of determining whether patients with diffuse large B-cell lymphoma (DLBCL) have bone marrow involvement – a development that should lead to better decisions about frontline treatment.

The study

Reporting in the August issue of the Journal of Nuclear Medicine , researchers led by Loius Berthet, M.D., carried out a retrospective study of 133 patients diagnosed with DLBCL. All patients underwent both a bone marrow biopsy and a whole-body 18F-FDG PET/CT scan.

Berthet said:

In our study, we showed that in diffuse large B-cell lymphoma, 18F-FDG PET/CT has better diagnostic performance than bone marrow biopsy to detect bone marrow involvement and provides a better prognostic stratification. While bone marrow biopsy is considered the gold standard to evaluate bone marrow involvement by high-grade lymphomas, 18F-FDG PET/CT is in fact the best method to evaluate extension of the disease, as well as avoid invasive procedures.

Compared to bone marrow biopsy, 18FDG PET/CT was:

  • More sensitive (94 percent vs. 24 percent)
  • Showed a higher negative predictive value (98 percent vs. 80 percent)
  • More accurate (98 percent vs. 81 percent)

The results

A total of 26 patients were found to have positive 18F-FDG PET/CT results but negative biopsy results. Eleven of them were restaged as stage IV by PET/CT. This effectively changed their treatment plans.

Added Berthet:

Our findings add to the literature to prove the significance of 18F-FDG PET/CT in cancer evaluation and to democratize this imaging method. Molecular imaging is the best method to adapt targeted therapies to each patient. The emergence of PET/MRI and novel radiotracers predicts an exciting new future for our field.

Source: snm.org

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...